secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0000950170-23-029500
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma reports FY2023 net loss of $42.4M, focuses on GTX-104 Phase 3
---------------------------------------------------------------------------

- Net loss of $42.4M ($0.95 loss per share) vs $9.8M loss prior year; impairments of $33.5M.
- Cash, cash equivalents and short-term investments $27.9M, expected to fund through Q2 2025 for potential NDA filing.
- FDA confirmed 505(b)(2) pathway for GTX-104; Phase 3 Safety Study protocol submitted, first patient H2 2023.
- Strategic realignment: R&D focus solely on GTX-104, evaluating partnerships for GTX-102/GTX-101.
- R&D expenses $9.9M (up 77% YoY); G&A expenses reduced to $7.6M; restructuring with layoffs in Canada.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023029500/0000950170-23-029500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000095017023029500/acst-20230623.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-029500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer